|
Delayed
Nasdaq
08:00:00 07/01/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 221.38 USD | +0.03% |
|
-.--% | +0.22% |
| 09/01 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2000 Value Benchmark | CI |
| 09/01 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2500 Value Benchmark | CI |
| Market Cap | 6.96B 6.01B 5.64B 5.13B 9.65B 665B 9.79B 66.07B 25.89B 333B 26.13B 25.56B 1,109B | P/E 2023 |
-3.03x | P/E 2024 | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 6.77B 5.85B 5.49B 5B 9.39B 648B 9.52B 64.3B 25.2B 324B 25.43B 24.88B 1,079B | EV / Sales 2023 |
0.64x | EV / Sales 2024 | 84.5x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: Cidara Therapeutics
| 1 day | +0.03% | ||
| Current year | +0.22% |
| Current year | 220.47 |  | 221.42 |
| 1 year | 59.8 | | 221.42 |
| 3 years | 10 | | 221.42 |
| 5 years | 8 | | 221.42 |
| 10 years | 8 | | 259 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Karbe
DFI | Director of Finance/CFO | 58 | 24/02/2025 |
Corrina Pavetto
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/1/26 | Issuer sale | Chief Financial Officer | 165,651 | 0.6532% | ||
| 7/1/26 | Issuer sale | Director | 35,375 | 0.1395% | ||
| 7/1/26 | Issuer sale | Chief Operating Officer | 241,829 | 0.9537% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 63.9M 55.17M 51.76M 47.14M 88.64M 6.11B 89.87M 607M 238M 3.06B 240M 235M 10.18B | 1.28M 1.1M 1.03M 941K 1.77M 122M 1.79M 12.11M 4.74M 61.08M 4.79M 4.68M 203M |
| Net income | -22.93M -19.8M -18.57M -16.92M -31.81M -2.19B -32.25M -218M -85.31M -1.1B -86.09M -84.23M -3.65B | -170M -147M -138M -125M -236M -16.24B -239M -1.61B -632M -8.14B -638M -624M -27.06B |
| Net Debt | -30.9M -26.68M -25.03M -22.8M -42.86M -2.95B -43.46M -293M -115M -1.48B -116M -114M -4.92B | -186M -161M -151M -137M -258M -17.81B -262M -1.77B -693M -8.92B -699M -684M -29.68B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CDTX Stock
Select your edition
All financial news and data tailored to specific country editions
